期刊文献+

HDAC2 siRNA转染人胰腺癌细胞对Bax和Bcl-2基因表达的影响 被引量:1

Effects of siRNA-mediated HDAC2 on the Expression of Apoptosis-related Genes of Bax and Bcl-2 in Human Pancreatic Cancer Cells PaTu8988
下载PDF
导出
摘要 目的:探讨组蛋白去乙酰化酶2(HDAC2)小干扰RNA(small interference RNA,siRNA)转染人胰腺癌细胞PaTu8988对凋亡相关基因Bax和Bcl-2表达的影响。方法:培养人胰腺癌细胞PaTu8988,将其随机分为三组:空白对照组、Negative SiRNA组、HDAC2SiRNA组,合成针对HDAC2基因的siRNA,利用阳离子脂质体(Lipofectamine2000)将HDAC2siRNA瞬时转染人胰腺癌细胞PaTu8988,应用免疫印迹法(Western blot)检测Bax和Bcl-2的表达。结果:与对照组和Negative SiRNA组对比,HDAC2siRNA组的Bax蛋白表达增加(P<0.01),Bcl-2蛋白的表达降低(P<0.01)。结论:采用siRNA干扰沉默人胰腺癌细胞HDAC2基因,可增加Bax的表达,抑制Bcl-2的表达。 Objective:To observe the effects of siRNA-mediated Histone Deacetylases 2(HDAC2)on the expression of apoptosis-related genes of Bax and Bcl-2in human pancreatic carncer cells PaTu8988.Methods:Human pancreatic cancer cell line PaTu8988 cells were cultured and divided into three groups:control group,negative siRNA group,HDAC2 siRNA group.Transient transfection of siRNA against HDAC2 on Human pancreatic cancer cells PaTu8988 were adopted by Lipofectamine 2000.Expression of Bax and Bcl-2genes were detected Western blot.Results:Compared with control group and negative siRNA group,the protein expression of Bax in HDAC2 siRNA group was obviously higher(P〈0.01),but the protein expression of Bcl-2in HDAC2 siRNA group was deeply decreased(P〈0.01).Conclusion:Transfection of HDAC2 siRNA in Human pancreatic cancer cells PaTu8988 can increase the expression of Bax gene,inhibit the expression of Bcl-2gene.
作者 闫岩 曹亮 YAN Yan CAO Liang(Department of Gastroenterology, the Affiliated Hospital of Jiangsu University, Zhenjiang City ,Jiangsu Province 212001)
出处 《医学理论与实践》 2017年第6期800-802,共3页 The Journal of Medical Theory and Practice
关键词 胰腺癌 组蛋白去乙酰化酶2 小RNA干扰 细胞凋亡 BAX基因 BCL-2基因 Pancreatic cancer HDAC2 siRNA-mediated Cell apoptosis Bax gene Bcl-2 gene
  • 引文网络
  • 相关文献

参考文献1

二级参考文献12

  • 1Mahlknecht U,Hoelzer D.Histone acetylation modifiers in the pathogenesis of malignant disease[J].Mol Med,2000,6(8):623-644.
  • 2Bracker TU,Sommer A,Fichtner I,et al.Efficacy of MS-275,a selective inhibitor of class Ⅰ histone deacetylases,in human colon cancer models[J].Int J Oncol,2009,35 (4):909-920.
  • 3Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
  • 4Li D,Xie K,Wolff R,et al.Pancreatic cancer[J].Lancet,2004,363 (9414):1049-1057.
  • 5Campbell PJ,Yachida S,Mudie LJ,et al.The patterns and dynamics of genomic instability in metastatic pancreatic cancer[J].Nature,2010,467(7319):1109-1113.
  • 6Witt O,Deuhzer HE,Milde T,et al.HDAC family:What are the cancer relevant targets?[J].Cancer Lett,2009,277(1):8-21.
  • 7Zhu P,Martin E,Menqwasser J,et al.Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis[J].Cancer Cell,2004,5 (5):455-463.
  • 8Fritsche P,Seidler B,Schüler S,et al.HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA[J].Gut,2009,58(10):1399-1409.
  • 9Karaqiannis TC,EI-Osta A.RNA interference and potential therapeutic applications of short interfering RNAs[J].Cancer Gene Ther,2005,12(10):787-795.
  • 10Glaser KB,Stayer MJ,Waring JF,et al.Gene expression profiling of multiple histone deaeetylase (HDAC)inhibitors:defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines[J].Mol Cancer Ther,2003,2(2):151-163.

共引文献1

同被引文献6

引证文献1

二级引证文献1

;
使用帮助 返回顶部